RevaMoraleMcCaskillMD

PubMed

• Upadacitinib in patients with psoriatic arthritis and inadequate response to biologics: 3-year results from the open-label extension of the randomised controlled phase...
  Philip Mease, Arathi Setty, Kim Papp, Filip Van den Bosch, Shigeyoshi Tsuji, Mauro Keiserman, Kyle Carter, Yihan Li, Reva McCaskill, Erin McDearmon-Blondell, Peter Wun...> ;Clinical and Experimental Rheumatology. 2023 Nov 1
• 10 citations
  Upadacitinib as monotherapy and in combination with non-biologic disease-modifying antirheumatic drugs for psoriatic arthritis.
  Peter Nash, Pascal Richette, Laure Gossec, Antonio Marchesoni, Christopher Ritchlin, Koji Kato, Erin L McDearmon-Blondell, Elizabeth Lesser, Reva McCaskill, Dai Feng, ...> ;Rheumatology. 2022 Aug 3
• 24 citations
  Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials.
  Gerd R Burmester, Kevin Winthrop, Ricardo Blanco, Peter Nash, Philippe Goupille, Valderilio F Azevedo, Carlo Salvarani, Andrea Rubbert-Roth, Elizabeth Lesser, Ralph Li...> ;Rheumatology and Therapy. 2022 Apr 1
• 34 citations
  Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study.
  Philip J. Mease, A. Lertratanakul, Kim A. Papp, Filip Van den Bosch, S. Tsuji, Eva Dokoupilova, M. Keiserman, Xianwei Bu, Liang Chen, R. Mccaskill, P. Zueger, E. Mcdea...> ;Rheumatology and Therapy. 2021 Apr 28
• 115 citations
  Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2
  Philip J. Mease, A. Lertratanakul, Jaclyn K Anderson, Kim A. Papp, Filip Van den Bosch, S. Tsuji, Eva Dokoupilova, M. Keiserman, X. Wang, Sheng Zhong, R. Mccaskill, P....> ;Annals of the Rheumatic Diseases. 2021 Mar 1
• Join now to see all